Screening for hepatocellular carcinoma

Area of Science:

• Hepatology
• Oncology
• Medical Diagnostics

Background:

• Liver cancer, specifically hepatocellular carcinoma (HCC), is a leading cause of cancer mortality worldwide.
• The cure rate for HCC has stagnated over the last two decades, highlighting the need for improved early detection and treatment strategies.
• Hepatocellular carcinoma predominantly arises in patients with underlying liver cirrhosis, regardless of its cause.

Purpose of the Study:

• To outline the rationale and methodology for screening programs targeting early detection of hepatocellular carcinoma in at-risk populations.
• To emphasize the importance of selecting patients with cirrhosis for screening who are candidates for effective treatment.
• To define the recommended screening modalities and frequency for liver cancer detection.

Main Methods:

• Screening programs for patients with cirrhosis are essential for early identification of hepatocellular carcinoma.
• The decision to screen should be based on the potential benefit from available treatments for diagnosed HCC.
• Recommended screening involves regular ultrasonography and alpha-fetoprotein level monitoring at 3–6 month intervals.

Main Results:

• Early detection of hepatocellular carcinoma through screening can lead to more effective treatment outcomes.
• Ultrasonography and alpha-fetoprotein serve as key diagnostic tools in current HCC screening protocols.
• Screening frequency should be adapted to community prevalence and economic factors.

Conclusions:

• Screening programs are crucial for improving outcomes in liver cancer patients with cirrhosis.
• Targeted screening ensures that diagnostic efforts are focused on individuals likely to benefit from HCC treatment.
• The implementation of ultrasonography and alpha-fetoprotein testing at regular intervals is vital for effective liver cancer surveillance.